EVALUATION OF ANTIDIABETIC DRUG ALOGLIPTIN FOR THE TREATMENT OF INFLAMMATION IN RATS

Abstract

Objective: The present study was planned to evaluate the Alogliptin (Anti diabetic drug) for the treatment of inflammation in experimental models in rats.

Methods: Total of  5 groups of wister rats of either sex weighing  180- 220 g, selected for the study of 2 animal model were kept at ambient temperature of 28±2°C and relative humidity of 45 to 55% with a 12:12 h light/dark cycle. The animals were fasted for 12 h before commencing the experiment with water ad libitum. Fasting was continued till completion of the experiment. Group A was served as normal toxicant control treated with toxicant Carrageenan (model 1) and Histamine (model 2), group B with Ibuprofen (40 mg/Kg p.o.) served as standard, groups C, D and E administered with Alogliptin (low, medium  and high doses p.o) respectively in each model. The Groups B, C, D and E were administered with 0.1 ml of 1% w/v of carrageenan in model 1,Histamine in model 2 into sub plantar region of right hind paw of rats 1 h after the administration of Ibuprofen/ Alogliptin. Immediately thereafter the oedema volumes of the injected paws were measured plethysmographically at prefixed time intervals.

Results: The Alogliptin with three selected doses i.e. 1, 2 and 3 mg/kg/day have exhibited a significant reduction in paw oedema volume at 4^th h in carrageenan 36.92%, 51.49%, 65.46% and histamine 27.41%, 48.24%, 69.07% respectively. Ibuprofen (40 mg/kg) was used as standard reference thus standard drug has exhibited time dependent reduction in oedema volume.

Conclusion: The results of recent studies suggest that dipeptidyl-peptidase-4 inhibitors (Alogliptin) have anti inflammatory effect on experimental models in rats.

     

Peer Review History:

Received 27 March 2018; Revised 10 May; Accepted 11 June; Available online 15 July 2018

Received file:        Reviewer's Comments:

Average Peer review marks at initial stage: 5.5/10

Average Peer review marks at publication stage: 9.5/10

Reviewer(s) detail:

Prof. Dr. Syamsudin Abdillah, Pancasila University, Indonesia, syamsudin.abdillah@gmail.com

Omnia Momtaz Al-Fakharany, Tanta, University, Eygpt, amina.elfakharany@pharm.tanta.edu.eg